After losing some value lately, a hammer chart pattern has been formed for Trevena (TRVN), indicating ... long-term analgesic effect in preclinical model of neuropathic pain, with no evidence ...

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a report released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.